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Edward E. Schmidt
Numerous genes are expressed
preferentially in spermatids, the
haploid germ cells of the testis.
Although some have defined,
spermatid-specific roles, the
expression and function of the
products of most of these genes are
not restricted to spermatids [1].
Examples include transcription
factors that have defined functions
elsewhere, kinases, metabolic
enzymes, and so on. Recently,
another group of proteins has been
added to this list — the components
of the basal RNA polymerase II (pol
II) transcription machinery [2].
Recent reports suggest that the
pol II machinery pre-assembles into
a holoenzyme complex [3,4]. The
levels of the components of this
complex coordinately increase 30- to
100-fold during the early haploid
stages of spermatogenesis ([2] and
unpublished observations). Thus,
early spermatid nuclei may have
much higher concentrations of
holoenzyme than do somatic cells. In
this light, it is interesting to consider
what would be the consequences of
increasing holoenzyme levels by two
orders of magnitude.
All models of transcriptional
regulation to date include the
assumption that the basal
transcription machinery is constant
and limiting; differences in the
activity of a promoter between cell
types have been presumed to result
solely from differences in the
‘attractiveness’ of that promoter for a
fixed concentration of pol II
machinery. Promoter attractiveness
can be regulated by altering DNA
methylation, chromatin structure or
transcription factor assemblages
[5–7]. But changes in the
concentration of holoenzyme might
also alter the rate of transcription
initiation at a promoter.
If the relative activities of the
three promoters depicted in Figure 1a
are plotted as a function of
holoenzyme concentrations, each
promoter gives a different activity
curve (Fig. 1c). Thus, changes in
holoenzyme concentration can affect
the activities of various promoters
differentially. For example, raising
the holoenzyme concentration from
1.0 to 100 arbitrary units activates
promoter C negligibly, whereas
promoter B, which is a weak promoter
at a holoenzyme concentration of 1.0,
is now activated to the point of being
nearly as strong as promoter C.
Interestingly, at elevated
holoenzyme concentrations, some
DNA sequences that do not normally
act as promoters — for example,
promoter A in the figure — may now
promote very strong transcription.
Is there any experimental
evidence to support such a model? A
recent paper [4] on mammalian RNA
polymerase II holoenzyme showed
that promoters which require
transcription factors for maximal
activity in vitro using crude nuclear
extracts (which have relatively low
holoenzyme concentrations) were
highly active in the absence of such
factors when supplied with a high
concentration of purified holoenzyme.
The addition of transcription factors
did not further activate transcription,
suggesting that at high holoenzyme
concentrations, weak and strong
promoters are similarly active. In other
studies [3], purified yeast holoenzyme
was shown to be responsive to
activators. Figure 1c shows how,
depending on holoenzyme
concentrations, promoters might
exhibit great differences in their
response to activators. 
What are the implications of this
model for spermatid-specific gene
expression? The model suggests that
many genes which are expressed in
spermatids might not require
spermatid-specific transcription
factors for their activation. Rather,
early spermatids, by having elevated
holoenzyme concentrations, may
provide a permissive environment for
transcription initiation. Thus, poor
promoters in particular should have
elevated activity in early spermatids
(Fig. 1c). The model is consistent
with the large number of genes that
are expressed in the testis, and with
the observation that testis-specific
expression frequently involves both
up-regulation of existing promoters
and recruitment of additional
promoters [1]. In contrast, genes for
abundant spermatid-specific proteins
have additional regulatory
mechanisms to ensure that the
difference in expression between
spermatids and other cell types is
orders of magnitude greater still [1,8].
The model proposed here does
not suggest that genes which are
expressed in spermatids, including
those with known functions
elsewhere, are expressed simply ‘by
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Figure 1
(a) Three hypothetical promoters with
different assemblies of transcription factors.
The dissociation constants for the interaction
of each promoter with holoenzyme are set at
100, 5 and 0.5 arbitrary units for promoters
A, B and C, respectively. The holoenzyme
and the promoter complexes are assumed to
be stable within the range of conditions
modeled. (b) Relative promoter activities at a
holoenzyme concentration of 1.0 arbitrary
units.  (c) Changes in holoenzyme
concentration differentially affect the
activities of the promoters without changing
the affinities of the promoters for holoenzyme.
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accident’. Rather, a mechanism is
proposed that could activate
transcription of numerous genes in
spermatids. If a gene is transcribed
and its protein accumulates in
spermatids, it is very possible that
the protein will function there.
Regulation of holoenzyme levels
might also contribute to other cases
of cell-type-specific gene regulation.
Although no other cells seem to
accumulate as much of the basal
transcription machinery as early
spermatids do, overall transcription
rates do vary by more than an order of
magnitude between different somatic
tissue types [9]. Thus, differences in
levels of the basal transcription
machinery may be of wide-spread
importance in determining patterns
of cell-type-specific gene expression.
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Essay
Two hundred years of
vaccination
Derrick Baxby
In a world in which infectious
diseases seem once again to be on the
increase, it is perhaps fitting that 1996
sees various events to commemorate
the first documented smallpox
vaccination, performed by Edward
Jenner on May 14 1796 [1]. This
article will consider Jenner’s claim to
fame and a few of the key events in
the 200 years of vaccination that have
followed his pioneering experiment.
Jenner has always been a
controversial figure who polarized
opinion, with even his supporters
divided on whether he was a genius
or a simple country doctor. That he
preferred life in Gloucestershire
rather than London is certain.
Nevertheless, by 1796 he was a well-
respected doctor-scientist, trained in
London by John Hunter, with a
general practice in Berkeley and a
consultant practice in fashionable
Cheltenham [2]. 
Jenner the naturalist
Although Jenner’s name is
inextricably linked with vaccination
he should still have been
remembered, particularly by
zoologists, for his studies on bird
behaviour, even if he had not
developed smallpox vaccine. It had
long been known that the female
cuckoo lays her eggs in the nests of
other birds. It was not known,
however, how the eggs and nestlings
of the foster parents were disposed
of; the foster parents and the female
cuckoo were variously thought to be
responsible. In 1787, Jenner
observed that it was the newly
hatched cuckoo which ejected the
eggs and nestlings of its foster
parents; for this work he was made a
Fellow of the Royal Society (FRS)
in 1789 [2,3]. 
In these studies, Jenner was not
content just to report observations:
he tried to determine how and why
the observed events occurred. For
example, he described the
anatomical modification to the back
of the newly hatched cuckoo which
facilitates its murderous activities,
and which disappears within about
12 days of hatching. He also
reasoned that the adult cuckoo laid
its eggs in other birds’ nests because
it only stayed in Britain for about 11
weeks and would not have enough
time to rear its young before it
departed. At a time when some still
believed that birds hibernated, he
showed that the impulse to migrate
was connected with changes in the
reproductive organs and not due to
climate or availability of food. With
this analytical attitude it was perhaps
inevitable that Jenner would become
interested in the control of disease.
Jenner and smallpox
In the 18th century, smallpox was a
major killer, leaving visible scars on
many survivors. Its importance can
perhaps most easily be appreciated by
showing its effects on the family of
King Charles I (Fig. 1). Attempts had
been made for many years to control
smallpox by ‘variolation’, the
deliberate inoculation of smallpox
virus into the skin in the hope that a
mild but immunizing disease would
result. There was a risk of severe
smallpox for the inoculated and their
contacts, however. 
Jenner, an experienced variolator,
became interested in the current folk
lore concerning cowpox and smallpox
in the late 1770s. The idea was that
those individuals — traditionally
milkmaids — who had recovered
from cowpox could not later contract
smallpox. Cowpox was a mild
localized infection and Jenner
collected circumstantial information
that seemed to confirm the
milkmaids’ story. On May 14 1796,
just before his 47th birthday, he
inoculated 8 year-old James Phipps
at two sites with material taken from
the hand of a milkmaid, Sarah
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